全文获取类型
收费全文 | 964篇 |
免费 | 40篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 42篇 |
妇产科学 | 3篇 |
基础医学 | 81篇 |
口腔科学 | 9篇 |
临床医学 | 101篇 |
内科学 | 267篇 |
皮肤病学 | 19篇 |
神经病学 | 6篇 |
特种医学 | 335篇 |
外科学 | 25篇 |
综合类 | 17篇 |
预防医学 | 22篇 |
眼科学 | 3篇 |
药学 | 70篇 |
中国医学 | 2篇 |
肿瘤学 | 22篇 |
出版年
2022年 | 2篇 |
2021年 | 8篇 |
2019年 | 3篇 |
2018年 | 8篇 |
2016年 | 3篇 |
2015年 | 7篇 |
2014年 | 10篇 |
2013年 | 8篇 |
2012年 | 10篇 |
2011年 | 11篇 |
2010年 | 15篇 |
2009年 | 18篇 |
2008年 | 16篇 |
2007年 | 29篇 |
2006年 | 22篇 |
2005年 | 15篇 |
2004年 | 11篇 |
2003年 | 14篇 |
2002年 | 12篇 |
2001年 | 16篇 |
2000年 | 13篇 |
1999年 | 20篇 |
1998年 | 49篇 |
1997年 | 46篇 |
1996年 | 59篇 |
1995年 | 44篇 |
1994年 | 34篇 |
1993年 | 42篇 |
1992年 | 16篇 |
1991年 | 14篇 |
1990年 | 22篇 |
1989年 | 43篇 |
1988年 | 46篇 |
1987年 | 38篇 |
1986年 | 43篇 |
1985年 | 44篇 |
1984年 | 31篇 |
1983年 | 25篇 |
1982年 | 28篇 |
1981年 | 31篇 |
1980年 | 14篇 |
1979年 | 6篇 |
1978年 | 9篇 |
1977年 | 28篇 |
1976年 | 18篇 |
1975年 | 15篇 |
1970年 | 2篇 |
1969年 | 1篇 |
1967年 | 3篇 |
1965年 | 1篇 |
排序方式: 共有1027条查询结果,搜索用时 275 毫秒
1.
R. Watson T. Kozlowski V. Nickeleit J. T. Woosley J. L. Schmitz S. L. Zacks J. H. Fair D. A. Gerber K. A. Andreoni 《American journal of transplantation》2006,6(12):3022-3029
Antibody-mediated rejection (AMR) after liver transplantation is recognized in ABO incompatible and xeno-transplantation, but its role after ABO compatible liver transplantation is controversial. We report a case of ABO compatible liver transplantation that demonstrated clinical, serological and histological signs of AMR without evidence of concurrent acute cellular rejection. AMR with persistently high titers of circulating donor specific antibodies resulted in graft injury with initial centrilobular hepatocyte necrosis, fibroedematous portal expansion mimicking biliary tract outflow obstruction, ultimately resulting in extensive bridging fibrosis. Immunofluorescence microscopy demonstrated persistent, diffuse linear C4d deposits along sinusoids and central veins. Despite intense therapeutic intervention including plasmapheresis, IVIG and rituximab, AMR led to graft failure. We present evidence that an antibody-mediated alloresponse to an ABO compatible liver graft can cause significant graft injury independent of acute cellular rejection. AMR shows distinct histologic changes including a characteristic staining profile for C4d. 相似文献
2.
BACKGROUND: The QT interval on the ECG is prolonged by more than 50 marketed drugs, an effect that has been associated with syncope and/or sudden cardiac death due to an arrhythmia. Because changes in heart rate also change the QT interval, it has become standard practice to use a correction formula, such as the Bazett formula, to normalize the QT interval to a heart rate of 60 bpm, that is, the rate-corrected QT or QTc. Numerous other formulas have been devised to make this correction, including the Fridericia, Hodges, and Framingham formulas. OBJECTIVES: The purpose of this study was to investigate how the Bazett formula and three other formulas influence assessment of the QT-prolonging effect of the potassium channel-blocking drug ibutilide. METHODS: Using a standardized physical activity protocol, the QT interval was assessed over a broad range of heart rates before and after an infusion of ibutilide (4.75 microg/kg) that produced a stable 15- to 20-ms QT prolongation in consenting normal subjects (9 men and 9 women). The QT interval was measured digitally over a range of heart rates from 60 to 120 bpm, and then four correction formulas (Bazett, Fridericia, Framingham, or Hodges) were applied. The uncorrected change in QT interval due to ibutilide was compared with the change using each of the formulas by repeated measures analysis of variance. RESULTS: At heart rates from 60 to 120 bpm, the Bazett and Fridericia correction formulas overestimated the change in QT in both men and women (P <.001). However, the Framingham and Hodges formulas did not alter the accuracy of the assessment of QT interval change. CONCLUSION: Rate correction of QT intervals using the standard Bazett and Fridericia formulas can introduce significant errors in the assessment of drug effects on the QT interval. This has implications for the clinical assessment of drug effects and for the safety assessment of new drugs under development. 相似文献
3.
4.
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. 总被引:2,自引:2,他引:0 下载免费PDF全文
C Funck-Brentano H K Kroemer H Pavlou R L Woosley D M Roden 《British journal of clinical pharmacology》1989,27(4):435-444
1. Quinidine is a potent inhibitor of the genetically-determined debrisoquine 4-hydroxylation. Oxidation reactions of several other drugs, including the 5-hydroxylation of the new antiarrhythmic drug propafenone, depend on the isozyme responsible for debrisoquine 4-hydroxylation. 2. The effect of quinidine on the debrisoquine phenotype-dependent 5-hydroxylation and the pharmacological activity of propafenone was studied in seven 'extensive' metabolizers and two 'poor' metabolizers of the drug receiving propafenone for the treatment of ventricular arrhythmias. 3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%. 4. Despite these changes in plasma concentrations, electrocardiographic intervals and arrhythmia frequency were unaltered by quinidine coadministration, indicating that 5-hydroxypropafenone contributes to the pharmacologic effects of propafenone therapy in extensive metabolizers. 5. In contrasts, plasma concentrations of propafenone and 5-hydroxypropafenone remained unchanged in the two patients with the poor metabolizer phenotype. 6. Biotransformation of substrates for the debrisoquine pathway can be markedly perturbed by even low doses of quinidine; interindividual variability in drug interactions may have a genetic component. 相似文献
5.
6.
7.
8.
A randomized controlled trial of electromagnetic therapy in the primary care management of venous leg ulceration 总被引:1,自引:1,他引:0
OBJECTIVE: The aim was to establish the potential efficacy, tolerabilityand side-effect profile of electromagnetic therapy as an adjunctto conventional dressings in the treatment of venous leg ulcers. METHOD: A prospective, randomized, double blind controlled clinicaltrial was carried out in a dedicated leg ulcer clinic basedin one urban general practice. Nineteen patients with leg ulcersof confirmed venous aetiology were assessed. The main outcomemeasures were rate and scale of venous leg ulcer healing, changesin patient-reported pain levels, quality of life, degree ofmobility, side effect profile and acceptability to patientsand staff. RESULTS: Sixty-eight per cent of patients attending this dedicated clinicachieved improvements in the size of their ulcer (4, 21%, healedfully) and in reduced pain levels (P < 0.05) during the trial,despite the chronicity of ulcer histories. Patients treatedwith electromagnetic therapy at 800 Hz were found at day 50to have significantly greater healing (P < 0.05) and paincontrol (P < 0.05) than placebo therapy or treatment with600 Hz. All patients reported improved mobility at the end ofthe study. The electromagnetic therapy was well tolerated bypatients, with no differences between groups in reporting adverseevents, and proved acceptable to staff. CONCLUSION: Despite the small numbers in this pilot study, electromagnetictherapy provided significant gains in the healing of venousleg ulcers and reduction in pain. Keywords. Electromagnetic therapy, RCT, leg ulcers, primary care. 相似文献
9.
10.